Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 28, 2012; 18(36): 5058-5064
Published online Sep 28, 2012. doi: 10.3748/wjg.v18.i36.5058
Published online Sep 28, 2012. doi: 10.3748/wjg.v18.i36.5058
Genetic variant | Sense primers | Antisense primers |
Arg702Trp | 5’-CAT CTG AGA AGG CCC TGC TC(C/T)-3’ | 5’-CAG ACA CCA GCG GGC ACA-3’ |
Gly908Arg | 5’-TTG GCC TTT TCA GAT TCT GG(G/C)-3’ | 5’-CCC CTC GTC ACC CAC TCT G-3’ |
Leu1007fs insC | Not available | Not available |
IGR2060a1 | 5’-CTC ATT ACA TCC TTG CAA CCC T(G/C)-3’ | 5’-GAC ACA TGG TGT GAG CTC AGT CA-3’ |
IGR3081a1 | 5’-TCG CGT GAG TCC TAT TCT TTC T(T/G)-3’ | 5’-TTC ATA CTT CCA GCA GCG GG-3’ |
Characteristic | Remaining in remission following discontinuing infliximab (n = 6) | Lost remission following discontinuing infliximab (n = 8) |
Male:female (n) | 4:2 | 4:4 |
Age of Crohn’s disease onset (yr), mean (range) | 30 (14-47) | 26 (15-38) |
Current age (yr), mean (range) | 53 (41-60) | 41 (25-57) |
Duration of disease prior to first infliximab infusion (yr), mean ± SD | 15 ± 8.0 | 10.1 ± 11.3 |
Age at first infliximab infusion (yr), mean ± SD | 45 ± 7.6 | 36 ± 11.1 |
Number of infusions, mean ± SD | 5.7 ± 3.5 | 4.7 ± 1.7 |
Duration of infliximab treatment (mo), mean (range) | 12 (3.6-36.2) | 7.2 (1.5-15) |
Duration of remission after infliximab stopped (yr), mean ± SD | 8.1 ± 2.61 | 1.0 ± 0.62 |
Disease distribution, n (%) | ||
Ileum | 2 (33) | 2 (25) |
Ileo-colonic | 3 (50) | 4 (50) |
Colon | 1 (17) | 2 (25) |
Current medications in patients who lost remission, n | ||
Adalimumab | 4 | |
Infliximab | 2 | |
Azathioprine alone | 1 | |
No Biological or immunosuppressive therapy3 | 1 |
Variant | Remaining in remission following discontinuing infliximab (n = 6) | Lost remission following discontinuing infliximab (n = 8) | Odds ratio | P value |
Arg702Trp | 1.50 | 1.00 | ||
Homozygous wild type, CC (%) | 4 (67) | 6 (75) | ||
Heterozygous, CT (%) | 2 (33) | 2 (25) | ||
Homozygous mutant, TT (%) | 0 | 0 | ||
Gly908Arg | - | - | ||
Homozygous wild type, GG (%) | 6 (100) | 8 (100) | ||
Leu1007fs insC | 2 (33) | 2 (25) | 1.50 | 1.00 |
IGR2060a1 | 1.67 | 1.00 | ||
Homozygous wild type, GG (%) | 1 (17) | 2 (25) | ||
Heterozygous, GC (%) | 3 (50) | 2 (25) | ||
Homozygous mutant, CC (%) | 2 (33) | 4 (50) | ||
IGR3081a1 | - | 0.47 | ||
Homozygous wild type, TT (%) | 0 | 2 (25) | ||
Heterozygous, GT (%) | 4 (66) | 2 (25) | ||
Homozygous mutant, GG (%) | 2 (33) | 4 (50) |
-
Citation: Lu C, Waugh A, Bailey RJ, Cherry R, Dieleman LA, Gramlich L, Matic K, Millan M, Kroeker KI, Sadowski D, Teshima CW, Todoruk D, Wong C, Wong K, Fedorak RN. Crohn’s disease genotypes of patients in remission
vs relapses after infliximab discontinuation. World J Gastroenterol 2012; 18(36): 5058-5064 - URL: https://www.wjgnet.com/1007-9327/full/v18/i36/5058.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i36.5058